会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • CHANNELED ENDOMURAL THERAPY
    • 通道内分泌治疗
    • WO2007047368A1
    • 2007-04-26
    • PCT/US2006/039891
    • 2006-10-13
    • ENDOLUMINAL THERAPEUTICS, INC.SLEPIAN, Marvin, J.
    • SLEPIAN, Marvin, J.
    • A61B17/22A61B17/00A61B18/24A61B17/88
    • A61B17/3207A61B17/00491A61B17/12022A61B17/12186A61B17/1219A61B17/12195A61B17/22A61B18/24A61B2017/00247A61B2017/1205A61B2017/22077A61B2018/00392A61K35/545
    • Diseases, aging, trauma, environmental exposure, infection and other events or agents can alter tissue function. In one embodiment, treatment is provided by therapeutically altering tissue function. This may be by continuing normal tissue function, suppressing tissue function, or enhancing tissue function. In a preferred embodiment, this treatment is effectuated by penetrating an organ, organ component or tissue structure and placing a supplemental material in a newly created space. This space is generally referred to herein as a "privileged space", i.e. a space not otherwise present in native tissue. Supplemental materials can be deposited and secured within the zone. Supplemental materials include materials forming barriers, supports, and/or materials that deliver agents having a pharmacologic, biochemical, or physiologic effect in vivo. Suitable supplemental materials include polymeric and non-polymeric materials, pharmacologic agents, cells, tissue fragments, microorganisms, viral agents, or other reagents modifying tissue function. The supplemental material is typically in the form of a reservoir/depot, or continuous or discontinuous layer. In one embodiment, supplemental materials, and methods of use thereof, are provided for the continuous or discontinuous therapy of defined regions of an organ, organ component or tissue structure. The supplemental materials may be delivered directly to any one or more of the three zones, endoluminal (or ectomural, for solid organs), endomural, or ectoluminal, of organs, organ components, or tissue structures. The supplemental materials can include natural or synthetic polymeric materials that are biodegradable or non-biodegradable. The supplemental materials can also contain bioactive agents to effectuate a change in an organ or organ component in need thereof. For example, agents that result in a reduced/hyponormal response or an amplified/hypernormal response may be included in the supplemental materials.
    • 疾病,衰老,创伤,环境暴露,感染和其他事件或代理可以改变组织功能。 在一个实施方案中,通过治疗改变组织功能来提供治疗。 这可以通过继续正常的组织功能,抑制组织功能,或增强组织功能。 在一个优选的实施方案中,这种治疗是通过穿透器官,器官组织或组织结构并将补充材料放置在新创建的空间中来实现的。 这个空间在本文中通常被称为“特许空间”,即不存在于天然组织中的空间。 补充材料可以在区域内沉积和固定。 补充材料包括形成障碍,支持物和/或材料的材料,其在体内递送具有药理学,生物化学或生理学作用的试剂。 合适的补充材料包括聚合物和非聚合物材料,药理学试剂,细胞,组织片段,微生物,病毒剂或修饰组织功能的其他试剂。 补充材料通常以储库/储库或连续或不连续层的形式存在。 在一个实施方案中,补充材料及其使用方法被提供用于器官,器官组分或组织结构的限定区域的连续或不连续治疗。 补充材料可以直接递送至三个区域中的任何一个或多个区域,腔内(或外部,用于实体器官),器官,器官组织或组织结构的腔内或腔外。 补充材料可以包括可生物降解或不可生物降解的天然或合成聚合物材料。 补充材料还可以含有生物活性剂以实现有需要的器官或器官组分的变化。 例如,导致降低的/低反应性反应或扩增/超常反应的药剂可以包括在补充材料中。
    • 8. 发明申请
    • CHANNELED ENDOMURAL THERAPY
    • 通道内膜治疗
    • WO2007047368A9
    • 2007-06-21
    • PCT/US2006039891
    • 2006-10-13
    • ENDOLUMINAL THERAPEUTICS INCSLEPIAN MARVIN J
    • SLEPIAN MARVIN J
    • A61B17/22A61B17/00A61B17/88A61B18/24A61F2/958
    • A61B17/3207A61B17/00491A61B17/12022A61B17/12186A61B17/1219A61B17/12195A61B17/22A61B18/24A61B2017/00247A61B2017/1205A61B2017/22077A61B2018/00392A61K35/545
    • Diseases, aging, trauma, environmental exposure, infection and other events or agents can alter tissue function. In one embodiment, treatment is provided by therapeutically altering tissue function. This may be by continuing normal tissue function, suppressing tissue function, or enhancing tissue function. In a preferred embodiment, this treatment is effectuated by penetrating an organ, organ component or tissue structure and placing a supplemental material in a newly created space. This space is generally referred to herein as a "privileged space", i.e. a space not otherwise present in native tissue. Supplemental materials can be deposited and secured within the zone. Supplemental materials include materials forming barriers, supports, and/or materials that deliver agents having a pharmacologic, biochemical, or physiologic effect in vivo. Suitable supplemental materials include polymeric and non-polymeric materials, pharmacologic agents, cells, tissue fragments, microorganisms, viral agents, or other reagents modifying tissue function. The supplemental material is typically in the form of a reservoir/depot, or continuous or discontinuous layer. In one embodiment, supplemental materials, and methods of use thereof, are provided for the continuous or discontinuous therapy of defined regions of an organ, organ component or tissue structure. The supplemental materials may be delivered directly to any one or more of the three zones, endoluminal (or ectomural, for solid organs), endomural, or ectoluminal, of organs, organ components, or tissue structures. The supplemental materials can include natural or synthetic polymeric materials that are biodegradable or non-biodegradable. The supplemental materials can also contain bioactive agents to effectuate a change in an organ or organ component in need thereof. For example, agents that result in a reduced/hyponormal response or an amplified/hypernormal response may be included in the supplemental materials.
    • 疾病,老化,创伤,环境暴露,感染等事件或药剂可改变组织功能。 在一个实施方案中,通过治疗性改变组织功能来提供治疗。 这可能是通过持续正常的组织功能,抑制组织功能或增强组织功能。 在优选的实施方案中,通过穿透器官,器官组分或组织结构并将补充材料放置在新创建的空间中来实现该治疗。 该空间在本文中通常被称为“特权空间”,即在天然组织中不存在的空间。 补充材料可以在区域内沉积并固定。 补充材料包括形成屏障,载体和/或递送在体内具有药理学,生物化学或生理学作用的物质的材料。 合适的补充材料包括聚合物和非聚合材料,药理学试剂,细胞,组织碎片,微生物,病毒试剂或修饰组织功能的其他试剂。 补充材料通常是储存器/储存器或连续或不连续层的形式。 在一个实施方案中,提供补充材料及其使用方法用于器官,器官组分或组织结构的限定区域的连续或不连续治疗。 补充材料可以直接递送到器官,器官成分或组织结构的内腔(或体外,对于固体器官),内膜或体腔内的三个区域中的任何一个或多个。 补充材料可以包括可生物降解或不可生物降解的天然或合成聚合材料。 补充材料还可以含有生物活性剂以实现有需要的器官或器官成分的变化。 例如,可以在补充材料中包括导致减少/低反应或者放大/超正常反应的药剂。